Viewing data from:

XEGLYZE

NDA

ABAMETAPIR | N206966 | LNHC INC

1 strength2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Expiring < 1yr (1)Active (1)Today

2027

2028

2029

2030

2031

2032

2033

2034

2035

Today

Oct. 28, 2026

Dec. 17, 2034

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain0 active DMFs1 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

MYLAN LABORATORIES LTDInactiveABAMETAPIR

DMF 343052019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jul 21, 2022	SUPPL -2	View Letter (PDF)
Jul 27, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.74%

RLD

2 patents0 exclusivities▴

LOTION;TOPICAL | Approved: Jul 24, 2020

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7812163	Oct 28, 2026	—	—	Yes		—
10292389	Dec 17, 2034	—	—	Yes		—